Rohto Pharmaceutical raised its earnings forecast for the fiscal year ending March 2027, sending its share price to a new year-to-date high. Strong first-quarter results and higher foreign-exchange assumptions are drawing market attention.
Rohto Pharmaceutical surged, with its current price reaching ¥2,862.5, up ¥500 from the previous day. This far exceeded the year-to-date high of ¥2,701 set in January.
The company revised upward its consolidated earnings forecast for the fiscal year ending March 2027, raising net sales from ¥369.5 billion to ¥372.3 billion, an 8.3% increase year on year, and operating income from ¥43.8 billion to ¥45.0 billion, a 9.4% increase. Its foreign-exchange assumptions were also revised in the direction of a weaker yen, with USD/JPY changed from ¥155 to ¥158 and the yuan-to-yen assumption from ¥22 to ¥23.
First-quarter results for April–June 2026 showed net sales of ¥91.624 billion, up 11.8% year on year, and operating income of ¥13.663 billion, up 16.8%. The Asia, Japan and Europe segments all delivered strong results above plan.